ILD Clinical Trials
The UCSF ILD Program is actively studying Interstitial Lung Diseases through several clinical research studies. Interested participants should contact: [email protected].
Interstitial Lung Disease Registry
The Interstitial Lung Disease Registry is a database of the clinical features of patients with interstitial lung disease that allows researchers to better define the characteristics of these diseases, their potential causes, and their natural history. The registry includes demographics, clinical metrics and survey questionnaires.
Interstitial Lung Disease Blood and Tissue Repository
The Interstitial Lung Disease Blood and Tissue Repository is a collection of serum, plasma, lung fluid, and lung tissue that is linked to the Interstitial Lung Disease Registry. These samples allow researchers to investigate biological mechanisms of disease and relate their findings to clinically important measures like symptom severity and disease progression.
JUNIPER: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
SLSIII- A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial studying the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD) with a combination of pirfenidone and Mycophenolate for treating scleroderma-related Interstitial Lung Disease.
PIRCLAD: An open label study testing the safety and tolerability of pirfenidone in patients with restrictive chronic lung allograft dysfunction.
EGCG: An open label study testing the safety epigallocatechin-3-gallate (EGCG) in patients with IPF.
TRAILS- Phase II study of safety, tolerability and efficacy of Pirfenidone in patients with Rheumatoid Arthritis Interstitial Lung Disease.
ISABELA: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis.
BI 1199.324: Investigating efficacy of pulmonary rehabilitation and in combination with nintedanib in patients with IPF.
Active Studies No Longer Enrolling
GA39831 Home Spirometry : An observational study to assess disease-relevant outcomes using home monitoring devices in patients with IPF.
BI 1199.225: A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD).
PRM 151: Continuation of a phase 2 Trial to Evaluate the Efficacy of pentraxin 2 (PRM-151) in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
LIBERATE: The purpose of this research is to study an investigational medical device that is designed to produce lung volume reduction in diseased areas of the lungs in patients with severe emphysema.
Recently Completed Studies
STX-003- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of STX-100 in Idiopathic Pulmonary Fibrosis.
1199.247- A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib over 52 weeks in patients with progressive fibrosing Interstitial Lung Disease (Non-IPF).
Pulmonary Fibrosis Foundation Registry- A multicenter, national, patient registry and biorepository for patients with Interstitial Lung Disease.
SENSCIS – A Double-Blind, Randomised, Placebo-Controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at least 52 weeks in Patients with 'Systemic Sclerosis associated Interstitial Lung Disease.
GBT Oxygen- A Phase II Randomized, Double-Blind, Placebo Controlled study of GBT440 to evaluate the safety, tolerability, pharmacokinetics and effect on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis.
PROMOTE- A Phase II Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of PRM-151 (recombinant human Pentraxin-2) in Subjects with Idiopathic Pulmonary Fibrosis.